E!12696 SpectraMed, SpectraCure AB (publ)
| Reference number | |
| Coordinator | SpectraCure AB (publ) |
| Funding from Vinnova | SEK 4 908 241 |
| Project duration | May 2019 - October 2021 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The project has been successful and has resulted in a medical device for the treatment of prostate cancer, where SpectraCure´s technology has been integrated with MedCom´s system for interventional navigation with ultrasound. The system is ready for use in further clinical trials for the treatment of prostate cancer.
Expected long term effects
The medical device developed in the project is planned to be used in clinical studies, and then form the basis for the launch of a commercial product.
Approach and implementation
In the project, two innovative SMEs have worked closely together to realize an integrated system for the treatment of prostate cancer. A large part of the project has been carried out during the pandemic, but without much impact thanks to the project organization quickly implementing digital tools for remote collaboration. In the final stages, some problems have arisen due to component shortages and delivery disruptions, but thanks to foresighted planning, the project has reached objectives in time.